Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
18 nov. 2024 08h40 HE
|
Silo Pharma, Inc.
Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions The Company is currently developing...
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
31 oct. 2024 08h35 HE
|
Silo Pharma, Inc.
The implant demonstrates stability and consistent drug release, supporting further analytical testing and development SARASOTA, FL, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
10 sept. 2024 06h35 HE
|
Silo Pharma, Inc.
Proposal submitted for FDA 505(b)(2) regulatory pathway for SPC-15 approval Advancing path to IND submission for first-in-human trials SARASOTA, FL, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ...
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
14 août 2024 14h30 HE
|
Silo Pharma, Inc.
SP-26 dissolvable ketamine-based injectable implant targets chronic pain and fibromyalgia Sever Pharma to scale-up extrusion processes and continue analytical testing for novel non-opioid treatment ...
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
07 août 2024 08h13 HE
|
Silo Pharma, Inc.
Silo to advance homing peptide development for initial indication in multiple sclerosis SARASOTA, FL, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the...
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
26 juil. 2024 08h20 HE
|
Silo Pharma, Inc.
Presentation to feature Silo’s novel therapeutics for the underserved SARASOTA, FL, July 26, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a...
Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
22 juil. 2024 16h45 HE
|
Silo Pharma, Inc.
SARASOTA, FL, July 22, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations...
Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
19 juil. 2024 08h01 HE
|
Silo Pharma, Inc.
SARASOTA, FL, July 19, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations...
Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
18 juil. 2024 08h25 HE
|
Silo Pharma, Inc.
Nose-to-Brain Drug Delivery Shows Promising Patient Safety and Therapeutic Benefit The Device and CMC Development Master Plan is designed to support IND-enabling studies SARASOTA, FL, July 18,...
Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic
16 juil. 2024 06h30 HE
|
Silo Pharma, Inc.
Agreement enhances Company’s intellectual property portfolio SARASOTA, FL, July 16, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage...